|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||93.03 - 93.03|
|52-week range||77.45 - 97.30|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||26.73|
|Forward dividend & yield||3.22 (3.43%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||N/A|
All children (100%) treated presymptomatically in the SPR1NT two-copy cohort survived without respiratory or nutritional support, and sat independently for ≥30 seconds, most (11/14) within the WHO window of expected normal development The majority of children (82%) treated in STR1VE-EU achieved developmental motor milestones not observed in the natural history of SMA Type 1, including patients with more severe disease More than 1,200 patients have now been treated with Zolgensma globally across
In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.